Difference between revisions of "Team:WHU-Pharm"

 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
{{TeamTemplateC}}
+
{{WHU-Pharm}}
 
<html>
 
<html>
 
<h1>WHU-Pharm Project Overview</h1>
 
<h1>WHU-Pharm Project Overview</h1>
  
−
<p>Our team aims to construct an in vitro insulin expression system that responds to different glucose concentrations. Insulin plays a crucial role in regulating blood glucose concentration and a lack of insulin secretion can cause diabetes. Currently diabetes patients have to inject insulin to keep their blood sugar level stable at approriate time (e.g., before meal). We hope to design an insulin expression system with the ability to detect surrounding glucose concentration, and insulin is produced only when glucose concentration reaches a threshold. To achive this, we combine the CRP activator, a regulatory protein activated by cAMP, with the gene sequence coding for insulin. Since glucose concentration is reversely related with cAMP level, a change of glucose level can influence the binding of CRP with target operon, thus altering the expression of downstream sequence. By expressing our desinged gene circuit with in vitro protein expression system, we will then test the expression level of the gene and find out how it relates with glucose concentration.
+
<p>Tumor cells are found to have increased ability to consume glucose due to their high growth rate, thus causing the surrounding glucose concentration to drop. Therefore, it is possible to discriminate tumor cells from other tissue cells by detecting the low glucose concentration. Using liposome as a vector, we hope to design a drug expression system with the ability to respond to different glucose level. To achieve this, we combine the CRP activator, a regulatory protein activated by cAMP, with red fluorescent protein (RPF) as a reporter of expression level. Since glucose concentration is reversely related with cAMP level, a change of glucose level can influence the binding of CRP with target operon, thus altering the fluorescent intensity. By expressing our desinged gene circuit with ''in vitro'' protein expression system, we then test the expression level of the gene and find out how it relates with glucose concentration.
 
</p>
 
</p>
 +
  
 
</div>
 
</div>
 
</html>
 
</html>

Latest revision as of 09:09, 15 September 2015

WHU-Pharm Project Overview

Tumor cells are found to have increased ability to consume glucose due to their high growth rate, thus causing the surrounding glucose concentration to drop. Therefore, it is possible to discriminate tumor cells from other tissue cells by detecting the low glucose concentration. Using liposome as a vector, we hope to design a drug expression system with the ability to respond to different glucose level. To achieve this, we combine the CRP activator, a regulatory protein activated by cAMP, with red fluorescent protein (RPF) as a reporter of expression level. Since glucose concentration is reversely related with cAMP level, a change of glucose level can influence the binding of CRP with target operon, thus altering the fluorescent intensity. By expressing our desinged gene circuit with ''in vitro'' protein expression system, we then test the expression level of the gene and find out how it relates with glucose concentration.